Designer Circular RNA as Protein Sponge for Cancer Therapy
The new circular RNA enables specific binding and inhibition of heterogeneous nuclear ribonucleoprotein L in cells and thus opens new therapeutic approaches for the treatment of pancreatic and other cancer types, where hnRNP L is deregulated.
The new circular RNA is very stable, it can easily be transfected into cells. It is used to sponge and thereby inhibit selectively hnRNP L.
Bilder & Videos
A new artificial circular RNA with an unusual ribonucleotide sequence was designed to bind and inhibit intracellular heterogeneous nuclear ribonucleoprotein L (hnRNP L). HnRNP L plays an essential role in the development of pancreatic and other cancer types.
- Circular RNA is much more stable than the corresponding linear RNA.
- Circular RNA can be designed to sponge RNA-binding proteins, thereby inhibiting the metabolic function of such proteins.
- Circular RNA can easily be introduced into cells and has no adverse side effects.
- A circular RNA was designed to bind hnRNP L with high specificity and affinity, inactivating this protein and thus opening up new therapy options for pancreatic and other cancer types, where hnRNP L is deregulated.
The new circular RNA is useful in pancreatic and oral squamous cell cancer therapy, when hnRNP L is overexpressed, based on binding and inhibiting intracellular heterogeneous nuclear ribonucleoprotein L (hnRNP L).
On behalf of its shareholder Justus-Liebig-Universität Giessen TransMIT GmbH is looking for cooperation partners or licensees for further development in Germany, Europe, US, and Asia.
StichworteCircular RNA, pancreatic cancer therapy, hnRNP L, heterogeneous nuclear ribonucleoprotein L, protein sponging, RNA-binding proteins, molecular medicine, oral squamous cell carcinoma therapy